95 related articles for article (PubMed ID: 20430616)
1. Discovery of potent, balanced and orally active dual NK1/NK3 receptor ligands.
Peters JU; Hoffmann T; Schnider P; Stadler H; Koblet A; Alker A; Poli SM; Ballard TM; Spooren W; Steward L; Sleight AJ
Bioorg Med Chem Lett; 2010 Jun; 20(11):3405-8. PubMed ID: 20430616
[TBL] [Abstract][Full Text] [Related]
2. Senktide-induced gerbil foot tapping behaviour is blocked by selective tachykinin NK1 and NK3 receptor antagonists.
Sundqvist M; Kristensson E; Adolfsson R; Leffler A; Ahlstedt I; Engberg S; Drmota T; Sigfridsson K; Jussila R; de Verdier J; Novén A; Johansson A; Påhlman I; von Mentzer B; Lindström E
Eur J Pharmacol; 2007 Dec; 577(1-3):78-86. PubMed ID: 17920583
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel NK1/NK3 dual antagonists for the potential treatment of schizophrenia.
Catalani MP; Alvaro G; Bernasconi G; Bettini E; Bromidge SM; Heer J; Tedesco G; Tommasi S
Bioorg Med Chem Lett; 2011 Nov; 21(22):6899-904. PubMed ID: 21974957
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potential dual NK(1)/NK(3) receptor antagonists.
Hanessian S; Babonneau V; Boyer N; Mannoury la Cour C; Millan MJ; De Nanteuil G
Bioorg Med Chem Lett; 2014 Jan; 24(2):510-4. PubMed ID: 24374277
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
6. Rational design of novel pyrrolidine derivatives as orally active neurokinin-3 receptor antagonists.
Ratni H; Ballard TM; Bissantz C; Hoffmann T; Jablonski P; Knoflach F; Knust H; Malherbe P; Nettekoven M; Patiny-Adam A; Riemer C; Schmitt M; Spooren W
Bioorg Med Chem Lett; 2010 Nov; 20(22):6735-8. PubMed ID: 20850972
[TBL] [Abstract][Full Text] [Related]
7. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective preparation of N-[(R,R)-(E)-1-(3,4-dichlorobenzyl)-3- (2-oxoazepan-3-yl)carbamoyl]allyl-N-methyl-3,5-bis(trifluoromethyl)benzamide, a potent and orally active dual neurokinin NK(1)/NK(2) receptor antagonist.
Gerspacher M; Lewis C; Ball HA; Howes C; Subramanian N; Ryffel K; Fozard JR
J Med Chem; 2003 Jul; 46(16):3508-13. PubMed ID: 12877589
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK(1) receptor antagonists.
Sabbatini FM; Di Fabio R; Griffante C; Pentassuglia G; Zonzini L; Melotto S; Alvaro G; Capelli AM; Pippo L; Perdona' E; St Denis Y; Costa S; Corsi M
Bioorg Med Chem Lett; 2010 Jan; 20(2):623-7. PubMed ID: 19963378
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel, potent and orally active series of gamma-lactams as selective NK1 antagonists.
Paliwal S; Reichard GA; Shah S; Wrobleski ML; Wang C; Stengone C; Tsui HC; Xiao D; Duffy RA; Lachowicz JE; Nomeir AA; Varty GB; Shih NY
Bioorg Med Chem Lett; 2008 Jul; 18(14):4168-71. PubMed ID: 18547807
[TBL] [Abstract][Full Text] [Related]
11. Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Di Fabio R; Griffante C; Alvaro G; Pentassuglia G; Pizzi DA; Donati D; Rossi T; Guercio G; Mattioli M; Cimarosti Z; Marchioro C; Provera S; Zonzini L; Montanari D; Melotto S; Gerrard PA; Trist DG; Ratti E; Corsi M
J Med Chem; 2009 May; 52(10):3238-47. PubMed ID: 19388677
[TBL] [Abstract][Full Text] [Related]
12. Activity of cyclic pseudopeptide antagonists at peripheral tachykinin receptors.
Patacchini R; Quartara L; Astolfi M; Goso C; Giachetti A; Maggi CA
J Pharmacol Exp Ther; 1995 Mar; 272(3):1082-7. PubMed ID: 7891319
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
Hoffmann T; Bös M; Stadler H; Schnider P; Hunkeler W; Godel T; Galley G; Ballard TM; Higgins GA; Poli SM; Sleight AJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1362-5. PubMed ID: 16332435
[TBL] [Abstract][Full Text] [Related]
14. Tetrahydroindolizinone NK1 antagonists.
Bao J; Lu H; Morriello GJ; Carlson EJ; Wheeldon A; Chicchi GG; Kurtz MM; Tsao KL; Zheng S; Tong X; Mills SG; DeVita RJ
Bioorg Med Chem Lett; 2010 Apr; 20(7):2354-8. PubMed ID: 20188553
[TBL] [Abstract][Full Text] [Related]
15. Molecular cloning, mutations and effects of NK1 receptor antagonists reveal the human-like pharmacology of gerbil NK1 receptors.
Engberg S; Ahlstedt I; Leffler A; Lindström E; Kristensson E; Svensson A; Påhlman I; Johansson A; Drmota T; von Mentzer B
Biochem Pharmacol; 2007 Jan; 73(2):259-69. PubMed ID: 17097619
[TBL] [Abstract][Full Text] [Related]
16. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain.
Sanger GJ
Br J Pharmacol; 2004 Apr; 141(8):1303-12. PubMed ID: 15023866
[TBL] [Abstract][Full Text] [Related]
17. Rolapitant (SCH 619734): a potent, selective and orally active neurokinin NK1 receptor antagonist with centrally-mediated antiemetic effects in ferrets.
Duffy RA; Morgan C; Naylor R; Higgins GA; Varty GB; Lachowicz JE; Parker EM
Pharmacol Biochem Behav; 2012 Jul; 102(1):95-100. PubMed ID: 22497992
[TBL] [Abstract][Full Text] [Related]
18. 2-Nitrophenylcarbamoyl-(S)-prolyl-(S)-3-(2-naphthyl)alanyl-N-benzyl-N - methylamide (SDZ NKT 343), a potent human NK1 tachykinin receptor antagonist with good oral analgesic activity in chronic pain models.
Walpole C; Ko SY; Brown M; Beattie D; Campbell E; Dickenson F; Ewan S; Hughes GA; Lemaire M; Lerpiniere J; Patel S; Urban L
J Med Chem; 1998 Aug; 41(17):3159-73. PubMed ID: 9703462
[TBL] [Abstract][Full Text] [Related]
19. Neurokinin receptor modulation of respiratory activity in the rabbit.
Bongianni F; Mutolo D; Cinelli E; Pantaleo T
Eur J Neurosci; 2008 Jun; 27(12):3233-43. PubMed ID: 18554294
[TBL] [Abstract][Full Text] [Related]
20. New quinoline NK3 receptor antagonists with CNS activity.
Smith PW; Wyman PA; Lovell P; Goodacre C; Serafinowska HT; Vong A; Harrington F; Flynn S; Bradley DM; Porter R; Coggon S; Murkitt G; Searle K; Thomas DR; Watson JM; Martin W; Wu Z; Dawson LA
Bioorg Med Chem Lett; 2009 Feb; 19(3):837-40. PubMed ID: 19117759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]